The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- NJ ACTS Success Story – The Kiosk Project
- Doctors Explain How to Tell the Difference Between Cold, Flu, and COVID-19 Symptoms.
- NJACTS Community Engagement Core COVID-19 Resources
- Join NJ ACTS Biostatistics, Epidemiology, Research Design (BERD)on 5/28 at 12pm
- Local infectious disease doctor says Hantavirus risk to public remains low.
Categories
- Community (2,489)
- Covid (1,001)
- CTO Events (6)
- News (3,160)
- Pilots (21)